Leap Frog Brushes Off Competition Worries and 4 Stock Analyses to Eye
Scripps Networks Interactive, Inc. (NYSE:SNI): Needham raised their price target for Scripps Networks Interactive, Inc. to reflect their fiscal year 2013 earnings estimate of $3.77 and keeps a Buy rating on the stock.
Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ): After meeting with Jazz Pharmaceuticals, Inc.’s management, Oppenheimer believes that investors are drawing “inappropriate parallels” between Jazz’s Xyrem and Questcor’s (NASDAQ:QCOR) Acthar drug. The firm thinks that concerns over Xyrem pricing are unwarranted and they maintain a $66 target and Outperform rating on Jazz.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Research In Motion Limited (NASDAQ:RIMM): Even after Research in Motion Limited reported better than expected results, Oppenheimer continues to anticipate that the company’s business will deteriorate over time. The firm maintains a Perform rating on their shares.
Pier 1 Imports Inc. (NYSE:PIR): After meeting with Pier 1’s Chief Financial Officer, Oppenheimer believes that the company is executing their three year strategic plan very well. The firm thinks the company’s online sales effort is encouraging and it maintains an Outperform rating on the stock.
LeapFrog Enterprises Inc. (NYSE:LF): BMO Capital believes that LeapFrog Enterprises Inc.’s stock has been pressured recently by fears of emerging competition in the children’s tablet space, but the firm thinks that the competition isn’t new and is targeting older children. LeapFrog’s LeapPad 2 seems to be selling very well. The firm maintains a $15 target and Outperform rating.
Don’t Miss: Sharp: Don’t Blame Us For the iPhone 5 Shortage.